![conference banner](/images/conference-banner.jpeg)
Abstract
Background: In utero exposure to Selective Serotonin Reuptake Inhibitors (SSRI) is considered a risk factor for many neurodevelopmental diseases.
Objective: The aim of this study was to investigate whether prenatal SSRI exposure changes newborn brain chemistry.
Methods: An animal-based study was designed in which the utero SSRI exposed rat pups were compared to one without drug exposure. Neurochemical changes in the infants were assessed after 2 days of birth by estimating the levels of inflammatory cytokines, neurotransmitters, and caspases in the brain exposed to SSRI at the prenatal stage and compared to normal unexposed newborns.
Results: Our results showed significant neurochemical changes in SSRI-exposed newborns. A significant decrease in dopamine, and serotonin levels with a remarkable decrease in noradrenaline in addition to remarkable increase of IFN-γ and caspase-3 levels was observed in the brain tissues of prenatal exposed SSRIs rat pups.
Conclusion: The results suggest that prenatal SSRI treatment may affect brain development of newborn hence should be done warily during the gestation period.
Keywords: Depression, neurotransmitters, pro-inflammatory cytokines, caspases, brain, SSRI.
Current Proteomics
Title:Neurochemical Changes in the Brain After Fetal Exposure to Fluoxetine, A Serotonin Reuptake Inhibitor (SRI) in Rodents
Volume: 18 Issue: 4
Author(s): Mona Awad Alonazi, Amina El Gezeery, Afaf El-Ansary and Ramesa Shafi Bhat*
Affiliation:
- Biochemistry Department, College of Science, King Saud University, Riyadh,Saudi Arabia
Keywords: Depression, neurotransmitters, pro-inflammatory cytokines, caspases, brain, SSRI.
Abstract:
Background: In utero exposure to Selective Serotonin Reuptake Inhibitors (SSRI) is considered a risk factor for many neurodevelopmental diseases.
Objective: The aim of this study was to investigate whether prenatal SSRI exposure changes newborn brain chemistry.
Methods: An animal-based study was designed in which the utero SSRI exposed rat pups were compared to one without drug exposure. Neurochemical changes in the infants were assessed after 2 days of birth by estimating the levels of inflammatory cytokines, neurotransmitters, and caspases in the brain exposed to SSRI at the prenatal stage and compared to normal unexposed newborns.
Results: Our results showed significant neurochemical changes in SSRI-exposed newborns. A significant decrease in dopamine, and serotonin levels with a remarkable decrease in noradrenaline in addition to remarkable increase of IFN-γ and caspase-3 levels was observed in the brain tissues of prenatal exposed SSRIs rat pups.
Conclusion: The results suggest that prenatal SSRI treatment may affect brain development of newborn hence should be done warily during the gestation period.
Export Options
About this article
Cite this article as:
Alonazi Awad Mona , El Gezeery Amina , El-Ansary Afaf and Bhat Shafi Ramesa *, Neurochemical Changes in the Brain After Fetal Exposure to Fluoxetine, A Serotonin Reuptake Inhibitor (SRI) in Rodents, Current Proteomics 2021; 18 (4) . https://dx.doi.org/10.2174/1570164617999201116154235
DOI https://dx.doi.org/10.2174/1570164617999201116154235 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
Call for Papers in Thematic Issues
Machine Learning Based Computational Biology and Digital Medicine
Machine learning has become a major research topic with a wide range of applications, such as intelligent driving, public security, financial risk management, medical diagnosis, and computational biology. This Special Thematic Issue entitled: "Recent Trends in Machine Learning Based Computational Biology and Digital Medicine" aims to explore the scientific-technological frontiers ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Astrocyte Infection by HIV-1: Mechanisms of Restricted Virus Replication, and Role in the Pathogenesis of HIV-1-Associated Dementia
Current HIV Research Targeting NO/cGMP Signaling in the CNS for Neurodegeneration and Alzheimer’s Disease
Current Medicinal Chemistry Significance of Hemodynamics Biomarkers, Tissue Biomechanics and Numerical Simulations in the Pathogenesis of Ascending Thoracic Aortic Aneurysms
Current Pharmaceutical Design Potential Therapeutic Targets for Neurodegenerative Diseases: Lessons Learned from Calorie Restriction
Current Drug Targets Cell-Penetrating Peptides as a Potential Drug Delivery System for Effective Treatment of Diabetes
Current Pharmaceutical Design An Effective Vaccination Approach Augments Anti-HIV Systemic and Vaginal Immunity in Mice with Decreased HIV-1 Susceptible α4β7high CD4+ T Cells
Current HIV Research Panicogens in Patients with Post-Traumatic Stress Disorder (PTSD)
Current Pharmaceutical Design Targeting Kit Activation: A Potential Therapeutic Approach in the Treatment of Allergic Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Probenecid: An Emerging Tool for Neuroprotection
CNS & Neurological Disorders - Drug Targets Thrombosis and Nephrotic Syndrome in Children
Current Pediatric Reviews Recent Applications of Birch Reduction in Total Synthesis of Natural Products
Current Organic Chemistry Membrane Targeted Chemotherapy with Hybrid Liposomes for Tumor Cells Leading to Apoptosis
Current Pharmaceutical Design Fc Receptors as Potential Targets for the Treatment of Allergy, Autoimmune Disease and Cancer
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Preformulation Stability Studies of a Proline Prodrug of Methotrexate
Medicinal Chemistry Saccharide Modified Pharmaceutical Nanocarriers for Targeted Drug and Gene Delivery
Current Pharmaceutical Design Pathogenesis of SLE Nephritis in the Era of Precision Medicine
Current Rheumatology Reviews Promotion of Remyelination by Immunoglobulins: Implications for the Treatment of Multiple Sclerosis
Current Pharmaceutical Design Reducing the Immunogenicity of Protein Therapeutics
Current Drug Targets Chemokine Signaling Defines Novel Targets for Therapeutic Intervention
Mini-Reviews in Medicinal Chemistry Gene Therapy Strategies Towards Immune Tolerance to Treat the Autoimmune Diseases
Current Gene Therapy